Brainstorm Cell TherapeuticsBCLI
13F holders, Q3 2025 (September 30)5holders −29
0new positions
29sold out
$0.75avg. 13F price*
At the end of Q3 2025, 5 institutions reported holding Brainstorm Cell Therapeutics (BCLI) in their 13F filings, down 29 from Q2 2025. 0 opened new positions and 29 sold out. The largest holders were Osaic Holdings, Inc. ($1K), Bangor Savings Bank ($188) and VSM Wealth Advisory, LLC ($85).
- Company
- Brainstorm Cell Therapeutics
- CUSIP
- 10501E300
- Latest filing quarter
- Q3 2025
History
Number of 13F holders
Total Exit/New Position Q2 2025 → Q3 2025
| Institutions | Total Value | |
|---|---|---|
| New Positions | 0 | $0 |
| Exits | 29 | $261K |
All 13F filers, Q2 2025 → Q3 2025: 390,470 shares sold, net −390,470 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 5 holders
| Osaic Holdings, Inc. | 0.00% | No change | 1,785 | $1K |
| Bangor Savings Bank | 0.00% | No change | 266 | $188 |
| VSM Wealth Advisory, LLC | 0.00% | No change | 120 | $85 |
| Steward Partners Investment Advisory, LLC | 0.00% | No change | 113 | $80 |
| St Germain D J Co. Inc. | 0.00% | No change | 33 | $23 |
"% of holder's portfolio" is BCLI's weight in each manager's 13F, not the share of Brainstorm Cell Therapeutics the manager owns.